ODAC to review Evista
Executive Summary
FDA's Oncology Drug Advisory Committee will review Lilly's Evista (raloxifene) for reduction in the risk of invasive breast cancer in postmenopausal women at high risk for breast cancer and those with osteoporosis July 24. Evista is approved for treatment and prevention of osteoporosis in postmenopausal women, which may help raloxifene gain ground in the cancer prevention market (1"The Pink Sheet" June 11, 2007, p. 14). GPC's satraplatin will also be discussed (2"The Pink Sheet" May 21, 2007, In Brief)...
You may also be interested in...
Lilly Evista Breast Cancer Market May Build On Osteo Acceptance
Physician experience in treating osteoporosis patients with Lilly's Evista (raloxifene) might improve the product's uptake for reducing the risk of breast cancer
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.